Evaluating ZS802 for treating Hemophilia A in Chinese patients

A Non-randomized, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of a Single Intravenous Infusion of ZS802 in Hemophilia A Subjects With Endogenous FVIII ≤2%.

This study is testing if a new treatment called ZS802 can help people with Hemophilia A in China by increasing their FVIII levels and reducing bleeding episodes.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 6 (estimated)
• Ages: 18 Years to 65 Years
• Sex: Male
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China (Academic / other)
• Locations: 1 site (Tianjin)
• Trial ID: NCT05523128 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety, tolerability, kinetics, and efficacy of a single intravenous infusion of ZS802 in patients with Hemophilia A who have low levels of endogenous FVIII. It is a non-randomized, open-label, dose-escalation study that will enroll six patients sequentially every three weeks. Participants will receive one of two dose levels of ZS802 and will be monitored for 52 weeks to evaluate the treatment's effects. The goal is to determine if ZS802 can effectively increase FVIII levels and reduce bleeding events.

Who should consider this trial

Good fit: Ideal candidates are males aged 18 to 65 with a confirmed diagnosis of Hemophilia A and endogenous FVIII levels of 2% or less.

Not a fit: Patients with FVIII levels above 2% or those who do not meet the inclusion criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with Hemophilia A by reducing bleeding episodes.

How similar studies have performed: While gene therapy approaches for Hemophilia A are being explored, this specific intervention with ZS802 is novel and has not been widely tested in previous studies.

Eligibility criteria

Inclusion Criteria:

1. Male ≥18 years and ≤65years of age;
2. Confirmed diagnosis of hemophilia A, and endogenous FVIII ≤2%:

   1. \<1% (\<1 IU/dL) endogenous FVIII activity levels as historically documented by a certified laboratory or screening data results; OR
   2. 1%-2% (1-2 IU/dL) endogenous FVIII activity levels and \>10 bleeding events per year (in the last 52 weeks prior to screening); OR
   3. 1%-2% (1-2 IU/dL) endogenous FVIII activity levels and on prophylaxis;
3. Have had ≥150 prior exposure days (EDs) to any recombinant and/or plasma-derived FVIII protein products.
4. Agree to use reliable barrier contraception and prohibition of sperm donation until 52 weeks after the administration of ZS802.
5. Subjects voluntarily participate and are fully informed, fully understand the research and can comply with the requirements of the research protocol, are willing to complete the research as planned, and voluntarily cooperate with the provision of biological samples for testing.

Exclusion Criteria:

1. Hypersensitivity to any component of the study drug (including immunosuppressants) or a condition that can not use.
2. Inability to tolerate immunosuppressants or steroid drugs.
3. Have no measurable FVIII inhibitor as assessed by laboratory; or documented no prior history of FVIII inhibitor.
4. Who have a history or are currently suffering from any of the following serious clinical diseases:

   1. History of malignancy or current presence of any malignancy;
   2. Have active autoimmune disease;
   3. Severe heart disease, including angina pectoris, myocardial infarction, heart failure, clinically significant congenital heart disease, heart valve disease, arrhythmia and atrioventricular block, etc.;
   4. Have underlying liver disease or history of liver disease (such as portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy or hepatic fibrosis);
   5. Have active hepatitis B infection (HBsAg positive or HBV-DNA positive) or active hepatitis C infection (HCVAb positive), or are currently receiving hepatitis B or hepatitis C antiviral therapy;
   6. Have history of chronic infection or other chronic disease that the Investigator considers to constitute an unacceptable risk;
   7. Diabetes mellitus that is poorly controlled after drug treatment;
   8. Uncontrolled hypertension or hypotension;
5. laboratory values:

   1. Hemoglobin\<110g/L;
   2. Platelets\<100×10\^9/L;
   3. AST, ALT, alkaline phosphatase\>2×ULN;
   4. Total bilirubin\>1.5×ULN;
   5. Creatinine\>ULN;
   6. Albumin\<LLN;
   7. HIV antibody positive or Treponema pallidum antibody positive.
6. Have AAV5 capsid neutralizing antibody titers \>1:5.
7. Those who have received clinical trials of gene therapy before screening, or have used FVIII clinical trial drugs within 1 month, or participated in other drug/device clinical trials within 3 months, or plan to participate in other clinical trials during this study.
8. Those who have planned surgery within 52 weeks after the infusion.
9. Those who donated or lost more than 400 mL of blood within 3 months before screening.
10. Those with epilepsy, history of mental illness (such as schizophrenia, depression, mania or anxiety) or obvious mental disorder, incapacitated or incapacitated by other reasons.
11. Patients with a history of drug abuse or alcoholism.
12. Investigators believe that subjects have poor compliance or are expected to be less likely to complete follow-up.
13. There are clinically significant diseases or other reasons that the researcher and/or collaborators consider unsuitable to participate in this researcher.

Where this trial is running

Tianjin

• Institute of Hematology & Blood Diseases Hospital — Tianjin, China (Recruiting)

Study contacts

• Principal investigator: Lei Zhang, MD — Institute of Hematology & Blood Diseases Hospital, China
• Study coordinator: Lei Zhang, MD

Conditions Hemophilia A; Gene therapy; Adeno-associated virus